Pharvaris NV PHVSannounced topline data from the RAPIDe-1 Phase 2 study, demonstrating statistically significant results of PHVS416 as an oral on-demand treatment for hereditary angioedema (HAE) attacks.
The study’s primary endpoint is the change of a three-symptom composite (skin pain, skin swelling, abdominal pain) visual analog scale (VAS-3) score from pre-treatment to four hours post-treatment.
Topline data from 147 attacks collected by 62 patients show that dose levels of PHVS416 significantly reduce attack symptoms.
All key secondary endpoints of the study were met, demonstrating that PHVS416 significantly Shortens the time to onset of symptom relief by a ≥30% reduction in VAS-3 score from the pre-treatment score.
PHVS416 was generally well tolerated, with no treatment-related serious adverse events and no adverse events leading to treatment discontinuation.
In August, the FDA placed clinical studies of PHA121, including RAPIDe-1 and CHAPTER-1, on hold.
After the clinical holds, the company continues to evaluate PHVS416 for acute attacks for continuing participants enrolled outside the U.S.
Topline data from CHAPTER-1 Phase 2 study of PHVS416, anticipated 2H2023.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
